AI Article Synopsis

  • Benzodiazepines, particularly chlordiazepoxide and diazepam, are commonly prescribed for managing alcohol withdrawal symptoms, while lorazepam is noted for its shorter action without active metabolites.
  • A study was conducted to compare the safety and efficacy of lorazepam and chlordiazepoxide in treating alcohol dependence syndrome among 60 patients with mild-to-moderate withdrawal symptoms, using a randomized double-blind design.
  • Results indicated that both medications significantly reduced withdrawal symptoms over 8 days, but there was no notable difference in effectiveness between the two drugs as measured by the CIWA-Ar scores.

Article Abstract

Background: Currently, benzodiazepines are the preferred drugs in the management of alcohol withdrawal symptoms. Chlordiazepoxide and diazepam, the most frequently used drugs have a long duration of action and are converted to active metabolites in the liver, while lorazepam is shorter acting, with no active metabolites.

Objective: To compare and evaluate the safety and efficacy of lorazepam and chlordiazepoxide in patients with alcohol dependence syndrome with symptoms of alcohol withdrawal.

Materials And Methods: This was a prospective, randomized, double-blind, study carried out at a teaching hospital in Bangalore. Sixty patients aged ≥18 y with alcohol dependence syndrome with mild-to-moderate withdrawal symptoms were allocated at a ratio of 1:1 to either lorazepam or chlordiazepoxide, by means of a computer-generated randomization chart. Thirty patients each were started with lorazepam tablets 8 mg/day and chlordiazepoxide 80 mg/day. For both treatment groups, the dose was tapered and at the end of 8 days, the patients were drug-free. The severity of alcohol dependence was assessed using the Severity of Alcohol Dependence Questionnaire (SADQ). The CIWA-Ar was used for quantification of withdrawal symptoms. Liver function tests were performed at baseline and at the end of the study.

Results: Of the 60 patients included in the study, 15 patients each had mild and moderate withdrawal symptoms in the chlordiazepoxide group and 17 and 13 patients respectively in the lorazepam group, based on the SADQ score. At baseline, the mean CIWA-Ar scores were similar in both the treatment groups: 24.77±5.98 in the chlordiazepoxide group and 24.90±6.12 in the lorazepam group. There was a significant intragroup decrease in the CIWA-Ar scores measured from baseline to the end of 8 days (p<0.0001) and 12 days (p<0.0001) in both treatment groups; however, there was no significant difference between the two groups. There was no significant difference observed in the liver function tests done at baseline and at the end of study period.

Conclusion: Lorazepam is noninferior to chlordiazepoxide in reducing alcohol withdrawal symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413079PMC
http://dx.doi.org/10.7860/JCDR/2015/11887.5678DOI Listing

Publication Analysis

Top Keywords

alcohol dependence
20
withdrawal symptoms
16
lorazepam chlordiazepoxide
12
dependence syndrome
12
symptoms chlordiazepoxide
8
treatment groups
8
severity alcohol
8
chlordiazepoxide group
8
lorazepam group
8
ciwa-ar scores
8

Similar Publications

Objective: Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.

View Article and Find Full Text PDF

Serious alcohol-associated hazards underscore the need to develop new biomarkers reflecting the biological changes caused by chronic alcohol use and predicting the risk of alcohol-related death. Oxidative stress is one mechanism of alcohol toxicity. The blood and urine redox status (total antioxidant capacity [TAC], total oxidative status [TOS], and oxidative stress index [OSI]) was assessed in 105 people who died a sudden death (controls), 47 people who died of alcohol overdose, and 102 people with alcohol dependency.

View Article and Find Full Text PDF

Photobiomodulation using an 830-nm laser alleviates hippocampal reactive gliosis and cognitive dysfunction in a mouse model of adolescent chronic alcohol exposure.

Pharmacol Biochem Behav

January 2025

Medical Laser Research Center, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea; Department of Biomedical Science, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea. Electronic address:

Chronic alcoholism is known to have detrimental effects on the brain, including cognitive impairment, neurotransmitter imbalances, and brain atrophy. The hippocampus, crucial for spatial memory and cognitive functions, is particularly susceptible to alcohol-induced changes. Photobiomodulation (PBM), a non-invasive therapeutic method that utilizes red or near-infrared light, has shown promising applications in the central and peripheral nervous systems.

View Article and Find Full Text PDF

Effects of Aminooxyacetic Acid on Learning and Memory Function and Neurochemical Changes in Chronic Alcoholism.

Brain Res Bull

January 2025

Sino-UK International Joint Laboratory of Brain Injury in Henan Province, Henan International Joint Laboratory of Neuromodulation, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China. Electronic address:

Objective: This study aimed to investigate the effect of aminooxyacetic acid (AOAA) on cognitive function, particularly learning and memory, in a rat model of chronic alcoholism. Additionally, the study explored changes in cystathionine β-synthase (CBS), hydrogen sulfide (H₂S), and serotonin (5-HT) levels in the prefrontal cortex to understand the potential neurochemical mechanisms involved.

Methods: Sixty-four male SD rats were randomly divided into four groups, with 16 rats in each: Con, Con + AOAA, Model, and Model + AOAA.

View Article and Find Full Text PDF

Introduction: There is strong evidence of the substance dependence has a negative impact on key dimensions of health. The scientific evidence suggests that pharmacological treatment could play a fundamental role in its clinical management.

Objective: The aim of this systematic review is to explore the existing pharmacological options for the treatment of substance use disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!